Biocomposite signed an exclusive agreement with LifeHealthcare to sell its STIMULAN® and genex® orthobiologic products in Australia.
LifeHealthcare focuses on infection, revision arthroplasty, oncology, limb deformity, paediatrics and biologics.
The genex platform is a versatile synthetic bone graft that supports natural healing and absorbs without a trace. The STIMULAN® Rapid Cure and STIMULAN® Kit products are absorbable and designed to be placed at the site of infection. STIMULAN is used in over 50,000 cases annually in thousands of hospitals around the world.
Michael Harris, Chief Executive Officer of Biocomposites, said, “Partnering with LifeHealthcare allows us to provide surgeons treating infected and high-risk patients with our innovative products – to improve patient outcomes, reduce hospital readmissions and lower overall treatment costs. This is another example of our strategy to partner with key players in our priority markets, which already includes agreements with the NHS in the U.K. and HealthTrust in the U.S.”
Biocomposite signed an exclusive agreement with LifeHealthcare to sell its STIMULAN® and genex® orthobiologic products in Australia.
LifeHealthcare focuses on infection, revision arthroplasty, oncology, limb deformity, paediatrics and biologics.
The genex platform is a versatile synthetic bone graft that supports natural healing and absorbs...
Biocomposite signed an exclusive agreement with LifeHealthcare to sell its STIMULAN® and genex® orthobiologic products in Australia.
LifeHealthcare focuses on infection, revision arthroplasty, oncology, limb deformity, paediatrics and biologics.
The genex platform is a versatile synthetic bone graft that supports natural healing and absorbs without a trace. The STIMULAN® Rapid Cure and STIMULAN® Kit products are absorbable and designed to be placed at the site of infection. STIMULAN is used in over 50,000 cases annually in thousands of hospitals around the world.
Michael Harris, Chief Executive Officer of Biocomposites, said, “Partnering with LifeHealthcare allows us to provide surgeons treating infected and high-risk patients with our innovative products – to improve patient outcomes, reduce hospital readmissions and lower overall treatment costs. This is another example of our strategy to partner with key players in our priority markets, which already includes agreements with the NHS in the U.K. and HealthTrust in the U.S.”
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Copy to clipboard 
